Cyclosporine and posttransplant hypertension

Area of Science:

• Nephrology
• Cardiology
• Transplantation

Background:

• Hypertension is highly prevalent in kidney transplant recipients, exceeding 50% and impacting both pediatric and adult populations.
• Cyclosporine use contributes significantly to hypertension rates in transplant patients.
• Cardiovascular disease is the primary cause of mortality in renal transplant recipients, making hypertension management critical.

Purpose of the Study:

• To summarize the prevalence and management of hypertension in kidney transplant patients.
• To highlight the role of cyclosporine in posttransplant hypertension.
• To discuss treatment strategies for hypertension in this vulnerable population.

Main Methods:

• Review of prevalence studies on hypertension in kidney transplant recipients.
• Analysis of factors contributing to posttransplant hypertension, including cyclosporine.
• Discussion of medical and surgical interventions for managing hypertension post-transplant.

Main Results:

• Hypertension is a common complication, with higher rates in pediatric kidney transplant recipients.
• Cyclosporine is a significant contributor to hypertension in both children and adults.
• Posttransplant hypertension is often mild to moderate, except in cases of transplant artery stenosis.
• Medical management, including diuretics and calcium channel blockers, is often effective.

Conclusions:

• Effective management of posttransplant hypertension is essential for improving long-term outcomes and reducing cardiovascular mortality.
• Balancing immunosuppression needs (cyclosporine dosage) with hypertension control is a key challenge.
• Diuretics and calcium channel blockers are recommended for cyclosporine-induced hypertension, with careful consideration of effects on renal function.